Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 5,565 shares at $251.98 ($1.4M) on 2024-11-27, disclosed to the SEC on 2024-11-27.
Scheduled sale ($1.4M) by CSO & EVP, Head of Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $247.77 | 26 | $6K | 0.5% |
| 2 | $249.60 | 215 | $54K | 3.8% |
| 3 | $250.68 | 318 | $80K | 5.7% |
| 4 | $250.68 | 318 | $80K | 5.7% |
| 5 | $251.42 | 826 | $208K | 14.8% |
| 6 | $251.42 | 826 |
| $208K |
| 14.8% |
| 7 | $252.27 | 84 | $21K | 1.5% |
| 8 | $250.45 | 210 | $53K | 3.8% |
| 9 | $250.45 | 210 | $53K | 3.8% |
| 10 | $251.98 | 851 | $214K | 15.3% |
| 11 | $251.98 | 851 | $214K | 15.3% |
| 12 | $253.44 | 360 | $91K | 6.5% |
| 13 | $253.44 | 360 | $91K | 6.5% |
| 14 | $254.48 | 110 | $28K | 2.0% |
| Total | $251.68 avg | 5,565 | $1.4M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |